BX-517 is a potent and selective PDK1 inhibitor (IC50 = 6 nM) that blocks Akt activation in tumor cells with an IC50 of 0.1–1.0 μM; it inhibits AKT2 activation in cells with submicromolar potency and exhibits ≥100-fold selectivity over a panel of seven additional Ser/Thr and Tyr kinases.